With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Zai Lab announces $200M share offering amid 47% revenue growth and plans for KarXT submission in China. Multiple companies report changes: Kronos Bio seeks alternatives, Allogene halts trial ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Investing.com - AbbVie (NYSE: ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...

Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

In September, the FDA approved the drug previously known as KarXT as a novel antipsychotic therapy for adults with schizophrenia. Citing new topline data from its 52-week open-label studies ...

Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to IQVIA RDS (India) for conducting the trial of KarXT, a ...